It was announced today that Intrinsiq
Materials Ltd. (IML) has secured exclusive, worldwide rights on a novel,
low temperature route to making nanoparticles for an undisclosed sum. The technology
was developed by a leading European chemical company, and the transfer of title
has been completed as part of a negotiated package. The technology transfer
was carried out during the first quarter of 2010.
The
acquired
technology
is
complementary
to
IML’s
existing
high
temperature
DC
plasma
processing
platform
that
already
produces
a
wide
range
of
highly
specified
inorganic
nanoparticles,
and
is
the
result
of
more
than
ten
years
of
development.
The
new
process
is
primarily
aimed
at
metal
nanoparticles
but
combines
broad
materials
and
processing
flexibility
with
scalability
for
industrial
uses
and
will
give
IML
increased
flexibility
in
the
design
and
development
of
their
nanoparticulate
products.
‘There
will
be
some
markets
and
materials
applications
where
clients
will
find
this
to
be
a
better
option
for
them
on
cost
or
performance’
said
Ian
Clark,
Sales
&
Marketing
Director
of
IML.
‘This
new
platform
has
the
potential
to
deliver
lower
cost
products
where
highly
specialised
processing,
such
as
the
rapid
cooling
or
the
exclusion
of
air
that
our
thermal
plasma
route
offers,
is
not
required’.
It
is
expected
that
products
from
this
system
will
be
developed
during
the
second
half
of
2010.
Intrinsiq
Materials,
which
focuses
primarily
on
Advanced
Materials
for
Printed
Electronics
and
the
Health
&
Wellness
sector,
was
spun
out
from
international
defence
and
security
company
QinetiQ
in
2007.
IML
has
positioned
itself
to
be
a
leading
materials
solution
company
focussing
at
the
nanoscale,
with
2
proprietary
platform
technologies:
i)
a
plasma
based
nanomaterial
manufacturing
technology
(Tesima®)
for
the
scaleable
production
of
novel
nanomaterials
and
ii)
a
nanoporous
silicon
technology.
In
addition
to
a
substantial
intellectual
property
portfolio
developed
since
the
1990s,
IML
maintains
its
HQ
and
nanomaterials
production
facility
in
Farnborough
UK
and
R&D
facility
in
Malvern
UK.
IML
is
currently
working
with
a
broad
set
of
international
customers
and
partners
on
nano
copper
and
silicon
inks,
nano
phosphors,
broad
spectrum
antimicrobial
nanoparticles
and
biocompatible
nanoporous
silicon
technology
to
improve
the
performance
of
consumer
care
products
as
well
as
improve
nutritional
delivery
from
performance
foods.